A committee of scientists, physicians, statisticians, and others that collects and analyzes data during the course of a clinical trial to monitor for adverse effects and other trends (such as an indication that one treatment is significantly better than another, particularly when one arm of the trial involves a placebo control) that would warrant modification or termination of the trial or notification of subjects about new information that might affect their willingness to continue in the trial. DSMBs are mandatory for all NIH funded Phase III studies, and are additionally needed for the following types of studies: emergency settings, large scale randomized clinical trials, multi-center clinical trials, blinded studies, multi-center Phase I and II trials, research involving high risk interventions or vulnerable population. Phase IV trials require a DSM plan.